Breaking News
0

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Gilead's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
65.74 +0.19    +0.29%
22/02 - Closed. Currency in USD ( Disclaimer )
After Hours
65.74
0.00
0.00%
17:25:04 - Real-time Data
Type: Equity
Market: United States
ISIN: US3755581036 
CUSIP: 375558103
  • Volume: 4,925,489
  • Bid/Ask: 65.58 / 65.90
  • Day's Range: 65.33 - 65.96
Gilead 65.74 +0.19 +0.29%

GILD Overview

 
Information about the Gilead Sciences Inc Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close65.55
Day's Range65.33 - 65.96
Revenue22.13B
Open65.61
52 wk Range60.32 - 82.72
EPS4.16
Volume4,925,489
Market Cap85.04B
Dividend (Yield)2.52 (3.84%)
Average Vol. (3m)7,970,094
P/E Ratio15.79
Beta1.19
1-Year Change - 17.2%
Shares Outstanding1,282,000,000
Next Earnings DateMay 02, 2019
What is your sentiment on Gilead?
or
Market is currently closed. Voting is open during market hours.

Gilead Sciences Inc News


Gilead Sciences Inc Analysis


Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Buy Sell Sell Strong Sell Sell
Technical Indicators Strong Buy Strong Sell Strong Sell Strong Sell Strong Sell
Summary Strong Buy Strong Sell Strong Sell Strong Sell Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Harami Bullish 1D Current
Completed Patterns
Three Outside Up 15 2 Feb 22, 2019 03:15PM
Bullish Engulfing 15 3 Feb 22, 2019 03:00PM
Engulfing Bearish 1M 4 Oct 18

Gilead Sciences Inc Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 65.74 65.58 65.90 4,925,489 +0.29% USD 22/02  
  Mexico 1,273.90 0.00 0.00 0 0.00% MXN 21/02  
  Switzerland 66.000 0.000 0.000 0 +0.00% CHF 14/02  
  Switzerland 67.000 0.000 0.000 0 0.00% USD 05/02  
  Frankfurt 58.04 57.96 58.03 2,201 -0.27% EUR 22/02  
  Berlin 57.800 57.970 58.010 50 -2.22% EUR 22/02  
  TradeGate 57.81 57.96 58.08 3,104 +0.16% EUR 22/02  
  Munich 57.740 0.000 0.000 0 -2.27% EUR 22/02  
  Xetra 58.1000 57.7500 58.4100 3,442 -0.02% EUR 22/02  
  Stuttgart 58.070 0.000 0.000 242 +0.10% EUR 22/02  
  Vienna 58.070 64.960 66.780 0 -1.81% EUR 21/02  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 172.97 173.00 171.38 +1.91 +1.12% 18.91M 22/02  
  Alphabet A 1,116.56 1,117.25 1,100.50 +12.35 +1.12% 1.47M 22/02  
  Facebook 161.89 162.41 160.31 +1.85 +1.16% 15.86M 22/02  
  Amazon.com 1,631.56 1,634.94 1,621.17 +12.12 +0.75% 3.10M 22/02  
  Vale ADR 12.500 12.510 12.170 +0.470 +3.91% 20.25M 22/02  
  Petroleo Brasileiro Petrobras ADR 16.63 16.75 16.53 -0.02 -0.12% 11.55M 22/02  
  Cleveland-Cliffs 11.580 11.640 11.420 +0.070 +0.61% 5.61M 22/02  
  Alibaba 176.92 177.02 172.52 +5.26 +3.06% 16.18M 22/02  
  Kraft Heinz 34.95 36.00 34.51 -13.23 -27.46% 135.20M 22/02  
  Boeing 424.05 424.47 419.14 +6.47 +1.55% 3.13M 22/02  

Gilead Sciences Inc Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

10000

Equity Type

ORD

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) $0 Start Trading
U.S. Commodity Futures Trading Commission (United States) Start Trading
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Padraig Crowley
Padraig Crowley Jul 06, 2018 8:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
am short GILD from $67 - anyone else think that the price will go lower than that at some stage over the summer?
Reply
0 3
태범 김
태범 김 Jul 06, 2018 4:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No. The company is poised for a major breakout upwards. It has positioned itself a leader in cell therapy with Kite Pharma acquisition, and has a strong base in the HIV market which is a huge cash cow, and still maintains considerable presence in Hepatitis B, C markets. . . While Hepatitis C market is bound to shrink, the company's anti-viral platform is not something that's to be looked over. . . Also coming out are NASH treatment regiments which if approved will be HUGE. . . There are some ifs to a bull case, but we all know that we have to place our bets in the defining moments.
Reply
2 0
yusuf zubir
yusuf zubir Jan 27, 2018 8:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any comment on earning? Momentum?
Reply
0 0
Sal Monella
Sal Monella Nov 16, 2017 6:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Typical WALL STREET fraud & theft! Company beats earnings estimates for 4 consecutive quarters TOP to BOTTOM & they crash the stock by 15% in following 3-4 weeks, after KITE acquisition & positive FDA Nescarta data. Even that greedy ***of a fraudster Jim Cramer was still telling people to sell in the low 70s. Please God. Next time, put Cramer in that bike path for the next lone wolf to run over.
Reply
0 4
Episcopolian OptionTrader
Episcopolian1 Oct 02, 2017 1:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$GILD The NASH Phase 2 data release iis now delayed until end-of-the-yea, possibly 1st qtr of 2018. Not good! but very good sign for $ICPT
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Oct 02, 2017 1:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sell $GILD and buy $ICPT
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Sep 28, 2017 10:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Floor chatter about Phase 2 NASH has failed!
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Sep 28, 2017 10:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A bad feeling about $GILD's COO retirement announcement, right before NASH announcement!!!
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Mar 17, 2017 9:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Price target raised to $110
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Mar 10, 2017 9:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
GILD is about to announce a huge acquisition. Buy it before that happens. $100 price target!.
Reply
0 0
Danny Alasha
Danny Alasha Dec 30, 2016 12:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job pop star, I see head and shoulders here but despite, 2017 pick
Reply
0 0
Nov 01, 2016 9:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I like what I see
Reply
0 0
Nov 01, 2016 9:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
That's right!:)
Reply
0 0
Pop Star
Pop Star Aug 19, 2016 5:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Headed to 86 in two weeks
Reply
0 0
Jeffrey Wright
Jeffrey Wright Apr 16, 2016 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Even after having to pay merk 200m?
Reply
0 0
David Simpson
David Simpson Feb 29, 2016 12:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What a bargain at these levels.....buy buy buy.
Reply
0 0
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email